Skip to content

Evaluation of the effectiveness of IVIg therapy on Covid 19 patients.

Evaluation of the effectiveness of IVIg therapy on blood (WBC? lymphocyte count), renal (Cr, urea) and liver parameters (AST, ALT) in COVID-19 patients before and after IVIg therapy.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20220213054013N1
Enrollment
196
Registered
2022-03-09
Start date
2022-03-01
Completion date
Unknown
Last updated
2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronavirus (Covid-19). COVID-19, virus identified

Interventions

Intervention 1: "Intervention group": In this study, patients with severe type or severity of COVID-19 disease, in addition to other treatments and according to the doctor, had a dose of IVIg treatmen

Sponsors

Esfahan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Having laboratory and clinical results of COVID-19 Positive PCR test for COVID-19 Do not have other allergic diseases and cancer

Exclusion criteria

Exclusion criteria: Taking any immunosuppressive drugs during treatment

Design outcomes

Primary

MeasureTime frame
Serum sodium level (Na). Timepoint: The day before the intervention and the fourth day after the intervention. Method of measurement: Measurement of sodium in the patient's blood in terms of milliequivalents per liter, before and after treatment until the fourth day after the intervention and comparison of the two groups using a flame photometer.;Potassium (K). Timepoint: The day before the intervention and the fourth day after the intervention. Method of measurement: Measurement of potassium in the patient's blood in milliequivalents per liter, before and after treatment until the fourth day after the intervention and comparison of the two groups using a flame photometer.;AST. Timepoint: The day before the intervention and the fourth day after the intervention. Method of measurement: Assessment of AST enzyme level before intervention and 4 days after comparison with control group using autoanalyzer.;ALT. Timepoint: The day before the intervention and the fourth day after the intervention. Method of measurement: Assessment of ALT enzyme level before intervention and 4 days after comparison with control group using autoanalyzer.;LDH. Timepoint: The day before the intervention and the fourth day after the intervention. Method of measurement: Assessment of LDH enzyme level before intervention and 4 days after comparison with control group using autoanalyzer.;D-dimer. Timepoint: The day before the intervention and the fourth day after the intervention. Method of measurement: Measurement of D-dimer before and 4 days in comparison with the control group using laboratory equipment.;ESR. Timepoint: The day before the intervention and the fourth day after the intervention. Method of measurement: Measurement of ESR before and 4 days compared to the control group using Westergreen method.;CRP. Timepoint: The day before the intervention and the fourth day after the intervention. Method of measurement: Measurement of CRP in patients' serum before and 4 days after the interventio

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBehrooz Ghezelbash

Esfahan University of Medical Sciences

behroozghezelbash@med.mui.ac.ir+98 31 3792 9231

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026